Better Efficacy of Synchrotron Spatially Microfractionated Radiation Therapy Than Uniform Radiation Therapy on Glioma.
Synchrotron microbeam radiation therapy (MRT) is based on the spatial fractionation of the incident, highly focused synchrotron beam into arrays of parallel microbeams, typically a few tens of microns wide and depositing several hundred grays. This irradiation modality was shown to have a high therapeutic impact on tumors, especially in intracranial locations. However, mechanisms responsible for such a property are not fully understood.



Thanks to recent progress in dosimetry, we compared the effect of MRT and synchrotron broad beam (BB) radiation therapy delivered at comparable doses (equivalent to MRT valley dose) on tumor growth control and on classical radiobiological functions by histologic evaluation and/or transcriptomic analysis.



MRT significantly improved survival of rats bearing 9L intracranial glioma compared with BB radiation therapy delivered at a comparable dose (P<.001); the efficacy of MRT and BB radiation therapy was similar when the MRT dose was half that of BB. The greater efficacy of MRT was not correlated with a difference in cell proliferation (Mki67 and proliferating cell nuclear antigen) or in transcriptomic stimulation of angiogenesis (vascular endothelial growth factor A or tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2) but was correlated with a higher cell death rate (factor for apoptosis signals) and higher recruitment of macrophages (tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 1 and CD68 transcripts) a few days after MRT.



These results show the superiority of MRT over BB radiation therapy when applied at comparable doses, suggesting that spatial fractionation is responsible for a specific and particularly efficient tissue response. The higher induction of cell death and immune cell activation in brain tumors treated by MRT may be involved in such responses.
Université Grenoble Alpes, Grenoble Institut des Neurosciences, Grenoble, France; Biomedical Beamline, European Synchrotron Radiation Facility, Grenoble, France. Electronic address: audrey.m.bouchet@gmail.com.
Audrey
A
Bouchet
Biomedical Beamline, European Synchrotron Radiation Facility, Grenoble, France.
Elke
E
Bräuer-Krisch
Biomedical Beamline, European Synchrotron Radiation Facility, Grenoble, France.
Yolanda
Y
Prezado
Université Grenoble Alpes, Grenoble Institut des Neurosciences, Grenoble, France; Grenoble University Hospital, Grenoble, France.
Michèle
M
El Atifi
Biomedical Beamline, European Synchrotron Radiation Facility, Grenoble, France.
Léonid
L
Rogalev
Biomedical Beamline, European Synchrotron Radiation Facility, Grenoble, France.
Céline
C
Le Clec'h
University of Bern, Bern, Switzerland.
Jean Albert
JA
Laissue
Université Grenoble Alpes, Grenoble Institut des Neurosciences, Grenoble, France; Grenoble University Hospital, Grenoble, France. Electronic address: laurent.pelletier@ujf-grenoble.fr.
Laurent
L
Pelletier
Biomedical Beamline, European Synchrotron Radiation Facility, Grenoble, France.
Géraldine
G
Le Duc
D000818:Animals; D001932:Brain Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D016371:Cranial Irradiation / Q000379:methods*; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005910:Glioma / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D000069473:Radiation Dose Hypofractionation; D020266:Radiotherapy, Conformal / Q000379:methods*; D011882:Radiotherapy, High-Energy / Q000295:instrumentation / Q000379:methods; D051381:Rats; D011916:Rats, Inbred F344; D017356:Synchrotrons / Q000295:instrumentation*; D016896:Treatment Outcome; D047368:Tumor Burden / Q000528:radiation effects